Kamada, which provides plasma-derived protein therapeutics mostly in Israel and the US, raised $52 million by offering 5.6 million shares at $9.25. Kamada plans to list on the NASDAQ under the symbol KMDA. Kamada initially filed confidentially on 1/24/2013. Morgan Stanley and Jefferies & Co. acted as lead managers on the deal.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
